# US 2021/0260181 A1 · Coronavirus immunogenic compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260181 A1
- Document ID: US20210260181A1
- Status: Published application
- Kind: A1
- Application number: 17/175,144
- Filed: 2021-02-12
- Published: 2021-08-26
- Earliest claimed: 2014-09-16
- Assignees: Altimmune Inc.
- Applicants: Altimmune, Inc
- Inventors: Bertrand Victor Gilbert Georges; M. Scot Roberts
- Web page: https://patentgrep.com/patent/US20210260181A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 9/0043: {Nose}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2750/14023: Virus like particles [VLP]
- C12N 2750/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.

## Claims

### Claim at position 1

1-62. (canceled)

### Claim 63

An immunogenic composition comprising a replication defective adenoviral (rdAd) vector comprising a nucleic acid sequence encoding SEQ ID NO: 446 or a variant comprising at least 95% identity to SEQ ID NO: 446.

### Claim 64 (depends on 63)

The immunogenic composition of claim 63, wherein the nucleic acid sequence encodes SEQ ID NO: 15.

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71 (depends on 63)

The immunogenic composition of claim 63, wherein the nucleic acid sequence encodes a sequence comprising one or more mutations selected from K417T, K417N, E484K, L452R and/or N501Y, wherein amino acid numbering corresponds to SEQ ID NO: 411.

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74 (depends on 63)

The immunogenic composition of claim 63, wherein the nucleic acid sequence encoding SEQ ID NO: 446 further comprises a leader sequence encoded by a nucleic acid sequence encoding a sequence selected from SEQ ID NOS: 418 to 437.

### Claim 75 (depends on 63)

The immunogenic composition of claim 63, wherein the coding sequence is codon optimized for a mammalian subject.

### Claim 76 (depends on 63)

The immunogenic composition of claim 63, wherein the replication defective adenoviral vector is a bovine adenovirus, a canine adenovirus, a non-human primate adenovirus, a chicken adenovirus, a porcine or swine adenovirus, or a human adenovirus.

### Claim 77 (depends on 76)

The immunogenic composition of claim 76, wherein the non-human primate adenovirus is a chimpanzee or gorilla adenovirus.

### Claim 78 (depends on 63)

The immunogenic composition of claim 63, wherein the replication defective adenoviral vector is a human adenovirus.

### Claim 79 (depends on 78)

The immunogenic composition of claim 78, wherein the human adenovirus is Ad5 or Ad26.

### Claim 80 (depends on 63)

A pharmaceutical formulation, comprising an effective amount of the immunogenic composition of claim 63, the composition comprising at least one pharmaceutically acceptable diluent or carrier.

### Claim 81 (depends on 80)

The pharmaceutical formulation of claim 80, configured for non-invasive or intranasal administration, wherein the pharmaceutically acceptable carrier is in a spray or aerosol form.

### Claim 82 (depends on 63)

A method for inducing an immune response against SARS-CoV-2, the method comprising administering an effective amount of the immunogenic composition of claim 63 to a human being.

### Claim 83 (depends on 82)

The method of claim 82, wherein the effective amount is at least 108 viral particles (vp), at least 109 viral particles (vp), or at least 1010 viral particles (vp).

### Claim 84 (depends on 82)

The method of claim 82, wherein the immunogenic composition is administered intranasally.

### Claim 85

(canceled)

### Claim 86 (depends on 82)

The method of claim 82, wherein the immune response against SARS-CoV-2 comprises a mucosal IgA and/or T cell response against SARS-CoV-2 induced after administration of the immunogenic composition.

### Claim 87 (depends on 82)

The method of claim 82, wherein the effective amount of the immunogenic composition reduces incidence of mild or moderate COVID-19-related diseases after the administration to the human subject.

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90 (depends on 82)

The method of claim 82, wherein the effective amount of the immunogenic composition reduces incidence of infection with SARS-CoV-2 after the administration to the human subject.

### Claim 91

(canceled)

### Claim 92 (depends on 82)

The method of claim 82, wherein the effective amount of the immunogenic composition reduces transmission of SARS-CoV-2 after the administration to the human subject.

### Claim 93

An immunogenic composition comprising a replication defective adenoviral (rdAd) vector comprising a nucleic acid sequence encoding SEQ ID NO: 15 or a variant comprising at least 95% identity to SEQ ID NO: 15.

### Claim 94

An immunogenic composition comprising an Ad5 human adenovirus replication defective adenoviral (rdAd) vector comprising a nucleic acid sequence encoding SEQ ID NO: 15 or a variant comprising at least 95% identity to SEQ ID NO: 15.
